CapsoVision, Inc. Common Stock (CV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CapsoVision, Inc. Common Stock stock (CV) is currently trading at $8.69. CapsoVision, Inc. Common Stock PS ratio (Price-to-Sales) is 24.59. Analyst consensus price target for CV is $10.50. WallStSmart rates CV as Sell.
- CV PE ratio analysis and historical PE chart
- CV PS ratio (Price-to-Sales) history and trend
- CV intrinsic value — DCF, Graham Number, EPV models
- CV stock price prediction 2025 2026 2027 2028 2029 2030
- CV fair value vs current price
- CV insider transactions and insider buying
- Is CV undervalued or overvalued?
- CapsoVision, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- CV Piotroski F-Score and Altman Z-Score
- CV analyst price target and Smart Rating
CapsoVision, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
CapsoVision, Inc. Common Stock (CV) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around operating margin and price/sales. Significant fundamental concerns warrant caution or avoidance.
CapsoVision, Inc. Common Stock (CV) Key Strengths (0)
Supporting Valuation Data
CapsoVision, Inc. Common Stock (CV) Areas to Watch (7)
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 24.6x annual revenue
Very expensive at 15.7x book value
Very low institutional interest at 1.67%
Small-cap company with higher risk but more growth potential
Solid revenue growth at 19.30% per year
Supporting Valuation Data
CapsoVision, Inc. Common Stock (CV) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (24.59), Price/Book (15.74) suggest expensive pricing. Growth concerns include Revenue Growth at 19.30%, which may limit upside. Profitability pressure is visible in Operating Margin at -226.70%, Profit Margin at -172.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -226.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 19.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CV's Price-to-Sales ratio of 24.59x sits near its historical average of 21.39x (87th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 52% below its historical high of 51.76x set in Dec 2025, and 65% above its historical low of 14.92x in Aug 2025. Over the past 12 months, the PS ratio has expanded from ~15.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for CapsoVision, Inc. Common Stock (CV) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
CapsoVision, Inc. Common Stock is a strong growth company balancing expansion with improving profitability. Revenue reached 13M with 19% growth year-over-year. The company is currently unprofitable, posting a -172.4% profit margin.
Key Findings
Debt-to-equity ratio of 0.05 indicates a conservative balance sheet with 18M in cash.
Spending 47% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -172.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact CapsoVision, Inc. Common Stock.
Bottom Line
CapsoVision, Inc. Common Stock offers an attractive blend of growth (19% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:21:24 AM
About CapsoVision, Inc. Common Stock(CV)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.